In vivo studies of activated porcine factor VIII

Thrombosis and Haemostasis

Volumn 76, Issue 5, 1996, Pages 743-748

  Littlewood, Janet D ^a   Bevan, Sally A ^b   Kemball Cook, Geoffrey ^c   Barrowcliffe, Trevor W ^b  

^a ANIMAL HEALTH TRUST   (United Kingdom)

^b NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; THROMBIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLEEDING TIME; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOG; DRUG ACTIVITY; DRUG BLOOD LEVEL; FEMALE; HEMOPHILIA; HEMOSTASIS; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL;

EID: 0029907935     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1650654     Document Type: Article

References (17)

1. Biggs R, Macfarlane RG, Denson KWE, Ash BJ. Thrombin aids the interaction of factors VIII and IX. Br J Haematol 1965; 11: 276-95.
2. Niemetz J, Nossel HL. Activated coagulation factors: in vivo and in vitro studies. Br J Haematol 1969; 16: 337-51.
3. Mertens K, van Wijngaarden A, Bertina RM The role of factor VIII in the activation of human blood coagulation factor X by activated factor IX. Thromb Haemost 1985; 54: 654-60.
4. Eaton D, Rodriguez H, Vehar GA. Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa and activated protein C with activation and inactivation of factor VIII coagulant activity. Biochemistry 1986; 25: 505-12.
5. Barrowcliffe TW, Edwards SJ, Kemball-Cook G, Thomas DP. Factor VIII degradation products in heated concentrates. Lancet 1986; 1: 1448-9.
6. Barrowcliffe TW, Watton J, Tubbs JE, Harman A, Kemball-Cook G. Potency of high purity factor VIII concentrates. Lancet 1990; 2: 124.
7. Barrowcliffe TW, Dawson NJ, Kemball-Cook G. Activated factor VIII in concentrates prepared by monoclonal antibody and recombinant technology. Thromb Haemost 1989; 62: 198.
8. Kemball-Cook G, Tubbs JE, Dawson NJ, Barrowcliffe TW. The behavio ur of different factor VIII concentrates in a chromogenic factor X-activating system. Br J Haematol 1993; 84: 273-8.
9. Giles AR, Tinlin S, Hoogendoom H, Greenwood R. A canine model of hemophilic (factor VIII:C deficiency) bleeding. Blood 1982; 60: 727-30.
10. Lollar P, Parker ET, Fay PJ. Coagulant properties of hybrid human/porcine factor VIII molecules. J Biol Chem 1992; 267: 23652-7.
11. Littlewood Janet D, Barrowcliffe TW. The development and characterisation of antibodies to human factor VIII in haemophilic dogs. Thromb Haemost 1987; 57: 314-21.
12. Giles AR, Tinlin S, Hoogendoorn H, Greenwood P, Greenwood R. Development of factor VIII:C antibodies in dogs with hemophilia A (factor VIII:C deficiency). Blood 1984; 63: 451-6.
13. Littlewood JD. Factor VIII-phospholipid mixtures and factor VIII inhibitors: studies in haemophilic dogs. PhD Thesis, University of Cambridge 1988.
14. Pijnappels MIM, Briet E, van der Zweet GTh, Huisden R, van Tilburg NH, Eulderink F. Evaluation of the cuticle bleeding time in canine haemophilia A. Thromb Haemost 1986; 55: 70-3.
15. Kirkwood TBL, Snape TJ. Biometrie principles in clotting and clot lysis assays. Clin Lab Haematol 1980; 2: 155-67.
16. Brinkhous KM, Sandberg H, Garris JB, Mattsson C, Palm M, Griggs T, Read SM. Purified human factor VIII procoagulant protein: comparative hemostatic response after infusion into hemophilic and von Willebrand disease dogs. Proc Natl Acad Sci USA 1985; 82: 8752-6.
17. Altieri DC, Capitanio AM, Mannucci PM. Von Willebrand factor contaminating porcine factor VIlI concentrate (Hyate C) causes platelet aggregation. Br J Haematol 1986; 63: 703-11.